Eiko LifesciencesBOM:540204 -1.43%78 EBITDA Margin % is 13.01% as of Mar. 2026, which is 32% above its 10-year median of 9.88. GuruFocus rates BOM:540204 with a GF Score™ of 78/100 and a GF Value™ of ₹78.58 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 1,579 Chemicals companies, Eiko Lifesciences ranks better than 71.82% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Eiko Lifesciences's EBITDA for the
three
months ended in Mar. 2026 was ₹23.9 Mil. Eiko Lifesciences's Revenue for the
three
months ended in Mar. 2026 was ₹183.4 Mil. Therefore, Eiko Lifesciences's EBITDA margin for the quarter that ended in Mar. 2026 was 13.01%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Eiko Lifesciences EBITDA Margin % Related Terms
Eiko Lifesciences EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Eiko Lifesciences's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:540204 vs LIN, SHW, ECL: EBITDA Margin % Comparison
For the Specialty Chemicals subindustry, Eiko Lifesciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eiko Lifesciences EBITDA Margin % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Eiko Lifesciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Eiko Lifesciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eiko Lifesciences (BOM:540204) has a EBITDA Margin % of 13.01% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Eiko Lifesciences and its competitors. This is 32% above median its historical median of 9.88. According to the industry distribution chart, Eiko Lifesciences ranks #445 out of 1579 companies in the Chemicals industry, placing it in the top 28.2%.
Is Eiko Lifesciences' EBITDA Margin % too high?
Eiko Lifesciences' current EBITDA Margin % of 13.01% is 32% above median its 10-year median of 9.88. The Chemicals industry median EBITDA Margin % is 9.63. Eiko Lifesciences' value of 13.01% is 35.1% above this industry median. Based on the distribution chart, Eiko Lifesciences ranks #445 out of 1579 companies in the Chemicals industry, which is above the industry midpoint. Overall, Eiko Lifesciences has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eiko Lifesciences' EBITDA Margin % compare to LIN and SHW?
According to the Chemicals industry distribution chart, Eiko Lifesciences ranks #445 out of 1579 companies for EBITDA Margin %. This puts Eiko Lifesciences in the upper half of its industry. The industry median EBITDA Margin % is 9.63. Eiko Lifesciences' value of 13.01% is 35.1% above this benchmark. While the company's 10-year median is 9.88 vs. the industry median of 9.63, Eiko Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Chemicals company?
The median EBITDA Margin % among Chemicals companies is 9.63, based on 1,579 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eiko Lifesciences's current EBITDA Margin % of 13.01% is 35.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Eiko Lifesciences and its competitors. For the Chemicals industry, the median EBITDA Margin % is 9.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eiko Lifesciences's current EBITDA Margin % is 13.01%, which is 32% above median its own 10-year median of 9.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eiko Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Eiko Lifesciences (BOM:540204) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹78.58, compared to a current price of ₹49.72 — trading 36.7% below its estimated fair value. The current EBITDA Margin % is 13.01%, which is 32% above median its 10-year median of 9.88 and 35.1% above the Chemicals industry median of 9.63. Eiko Lifesciences' overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Eiko Lifesciences (BOM:540204), the current EBITDA Margin % is 13.01% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eiko Lifesciences (BOM:540204) Overvalued in 2026?
Based on GuruFocus' analysis, Eiko Lifesciences stock appears to be undervalued.
The current stock price of ₹49.72 is trading 36.7% below its estimated GF Value™ of ₹78.58.
GuruFocus considers Eiko Lifesciences to be Significantly Undervalued.
Key valuation signals for BOM:540204:
EBITDA Margin %: 13.01% (32% above median its 10-year median of 9.88)
GF Value™: ₹78.58 vs. price of ₹49.72 (36.7% below fair value)
Industry Position: 35.1% above the Chemicals median (#445 of 1579)
No single metric tells the full story. See the BOM:540204 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eiko Lifesciences Ltd is a manufacturer, supplier, and exporter of specialty chemicals, fine chemicals, and pharma intermediates.. The company's segment includes Agrochemicals, Oleo Chemicals, Pharmaceuticals, Food Additives, clinical research, development, and Logistics. Geographically, the company generates the majority of its revenue from the Domestic market.
78GF Score
Get the complete analysis for BOM:540204
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540204 has been successfully added to your 
